RET-KIF5B (Kex15Rex14)

KIF5B-RET · Variant type: fusion · Fusion partner: KIF5B (Kex15Rex14)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	99.6%	0.4%	93.43
2	Fedratinib	99.3%	0.7%	96.21
3	Tenalisib	99.2%	0.8%	97.98
4	Alpelisib	99.0%	1.0%	97.22
5	Entrectinib	98.7%	1.3%	93.69
6	Tivozanib	98.2%	1.8%	92.42
7	Lenvatinib	98.2%	1.9%	97.74
8	Alectinib	97.7%	2.3%	95.49
9	Selpercatinib	97.2%	2.8%	96.72
10	Regorafenib	97.0%	3.0%	95.99
11	Cabozantinib	96.5%	3.5%	92.73
12	Brigatinib	96.2%	3.8%	82.96
13	Futibatinib	96.1%	3.9%	98.48
14	Gilteritinib	95.9%	4.1%	88.97
15	Ripretinib	94.2%	5.8%	92.95
16	Vandetanib	93.7%	6.3%	95.74
17	Sorafenib	92.9%	7.1%	96.72
18	Sunitinib	92.8%	7.2%	91.73
19	Erdafitinib	89.8%	10.2%	95.71
20	Fostamatinib	89.6%	10.4%	96.74
21	Apatinib	87.0%	13.0%	97.73
22	Ibrutinib	87.0%	13.0%	94.74
23	Repotrectinib	86.2%	13.8%	84.21
24	Pazopanib	81.6%	18.4%	97.49
25	Avapritinib	81.6%	18.4%	97.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	99.6%	—	—
Fedratinib	99.3%	—	—
Tenalisib	99.2%	—	—
Alpelisib	99.0%	—	—
Entrectinib	98.7%	—	—
Tivozanib	98.2%	—	—
Lenvatinib	98.2%	—	—
Alectinib	97.7%	—	—
Selpercatinib	97.2%	—	—
Regorafenib	97.0%	—	—
Cabozantinib	96.5%	—	—
Brigatinib	96.2%	—	—
Futibatinib	96.1%	—	—
Gilteritinib	95.9%	—	—
Ripretinib	94.2%	—	—
Vandetanib	93.7%	—	—
Sorafenib	92.9%	—	—
Sunitinib	92.8%	—	—
Erdafitinib	89.8%	—	—
Fostamatinib	89.6%	—	—
Apatinib	87.0%	—	—
Ibrutinib	87.0%	—	—
Repotrectinib	86.2%	—	—
Pazopanib	81.6%	—	—
Avapritinib	81.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.1ms